Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond.  Our clinical stage products target specific cancers at the molecular level, and our companion diagnostics identify the patients with the corresponding molecular signature who are the best candidates for therapy.   Our products are based on our proprietary peptide targeted radionuclide technology which can image and subsequently kill cancer cells with directed radiotherapy. Three clinical trials with Tozaride (Re188-P2045) have been completed and Phase 2 studies are being planned. Our team, with more than 75 years combined experience, is committed to creating treatments that produce significant and improved outcomes for cancer patients.